<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880642</url>
  </required_header>
  <id_info>
    <org_study_id>VP-C21-008</org_study_id>
    <nct_id>NCT04880642</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects</brief_title>
  <acronym>ATTRACT-3</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as Add on to Standard of Care in Adult Subjects With COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicore Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vicore Pharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm,&#xD;
      multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add on to SoC&#xD;
      in adult subjects with COVID-19.&#xD;
&#xD;
      The trial will enroll a total of 600 randomized subjects, 300 per arm (oral C21 100 mg twice&#xD;
      a day (b.i.d.) or placebo for 14 days) according to the 1:1 randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of 3 consecutive periods: a screening period of up to 48 hours, a 2-week&#xD;
      IMP treatment period and a follow-up period of up to 7 weeks after last IMP intake.&#xD;
&#xD;
      All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety&#xD;
      laboratory tests and samples for future exploratory analysis will be obtained at the&#xD;
      screening visit.&#xD;
&#xD;
      The trial duration for an individual subject will not exceed 9 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects discharged from hospital and free of supplemental oxygen</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supplemental oxygen free days</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects free of respiratory failure</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained hospital discharge</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of withdrawals due to Adverse events</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects discharged from hospital and free of supplemental oxygen</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects discharged from hospital and free of supplemental oxygen</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects discharged from hospital and free of supplemental oxygen</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of hospitalized subjects on non-invasive, invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or supplemental oxygen use</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of hospitalized subjects on non-invasive, invasive mechanical ventilation, ECMO or supplemental oxygen use</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of hospitalized subjects on non-invasive, invasive mechanical ventilation, ECMO or supplemental oxygen use</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of hospitalized subjects on non-invasive, invasive mechanical ventilation, ECMO or supplemental oxygen use</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of hospitalized subjects on non-invasive, invasive mechanical ventilation, ECMO or supplemental oxygen use</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects in each category of the 8-point ordinal scale</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects in each category of the 8-point ordinal scale</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects in each category of the 8-point ordinal scale</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects in each category of the 8-point ordinal scale</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects in each category of the 8-point ordinal scale</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of hospitalization, including re-hospitalization</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects needing intensive care unit stay</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects needing intensive care unit stay</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects needing intensive care unit stay</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects needing intensive care unit stay</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects needing intensive care unit stay</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of intensive care unit stay, including re-admission</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects on invasive mechanical ventilation or ECMO</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects on invasive mechanical ventilation or ECMO</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects on invasive mechanical ventilation or ECMO</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects on invasive mechanical ventilation or ECMO</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects on invasive mechanical ventilation or ECMO</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory failure free days</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in oxygen saturation/ fraction of inspired oxygen</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in C-reactive protein concentration</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>C21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg capsules, oral administration twice daily,for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules, oral administration twice daily,for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C21</intervention_name>
    <description>C21</description>
    <arm_group_label>C21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years or the legal age of consent in the jurisdiction in which the trial is&#xD;
             taking place at the time of signing the informed consent&#xD;
&#xD;
          2. Hospitalized due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)&#xD;
             infection confirmed by polymerase chain reaction test, documented by either of the&#xD;
             following:&#xD;
&#xD;
               1. Polymerase chain reaction (PCR) positive in sample collected &lt;72 hours prior to&#xD;
                  randomization (Visit 2); OR&#xD;
&#xD;
               2. PCR positive in sample collected ≥72 hours and ≤7 days prior to randomization,&#xD;
                  documented inability to obtain a repeat sample AND progressive disease suggestive&#xD;
                  of ongoing SARS-CoV-2 infection&#xD;
&#xD;
          3. A score of 5 or 6 on the 8-point ordinal scale:&#xD;
&#xD;
               1. Score 5: Hospitalized, requiring supplemental oxygen&#xD;
&#xD;
               2. Score 6: Hospitalized, on non-invasive ventilation or high-flow oxygen device&#xD;
&#xD;
          4. Contraceptive use by men and women of childbearing potential consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies&#xD;
&#xD;
          5. Written informed consent, consistent with International Council for Harmonization Good&#xD;
             Clinical Practice Revision 2 and local laws, obtained before the initiation of any&#xD;
             trial- related procedure&#xD;
&#xD;
          6. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form and in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent serious medical condition which in the opinion of the investigator&#xD;
             constitutes a risk or a contraindication for the participation in the trial or that&#xD;
             could interfere with the trial objectives, conduct or evaluation&#xD;
&#xD;
          2. Known, active hepatitis B, C, or human immunodeficiency virus infection (i.e., human&#xD;
             immunodeficiency virus (HIV) with a cluster of differentiation 4 (CD4) count &lt;500&#xD;
             cells/mm³)&#xD;
&#xD;
          3. Impaired hepatic function (i.e., Child-Pugh class A or B)&#xD;
&#xD;
          4. Severe renal impairment (i.e., estimated glomerular filtration rate (eGFR) ≤30&#xD;
             ml/min/1.73 m2)&#xD;
&#xD;
          5. Corona virus disease (COVID)-19 symptom onset &gt;14 days prior to screening&#xD;
&#xD;
          6. Hospitalized due to COVID-19 for &gt;72 hours at screening&#xD;
&#xD;
          7. Invasive mechanical ventilation or ECMO within 72 hours of screening&#xD;
&#xD;
          8. Expected need for invasive mechanical ventilation or ECMO in &lt;48 hours in the opinion&#xD;
             of the investigator&#xD;
&#xD;
          9. Moderate to severe ARDS (e.g., partial pressure of oxygen (PaO2)/FiO2 ≤200 mmHg), if&#xD;
             on non-invasive mechanical ventilation or high-flow oxygen&#xD;
&#xD;
         10. Pregnant or breast-feeding female subjects&#xD;
&#xD;
         11. Any previous and concurrent experimental treatment for COVID-19 that is not considered&#xD;
             local SoC.&#xD;
&#xD;
         12. Treatment with the medications listed below within 1 week prior to screening or&#xD;
             anticipated need for such medication during the participation in this trial:&#xD;
&#xD;
               1. Strong Cytochrome P450 (CYP) 3A4 inducers.&#xD;
&#xD;
               2. P-glycoprotein (P-gp) substrates with narrow therapeutic index.&#xD;
&#xD;
               3. High dose Breast Cancer Resistance Protein (BCRP) sensitive substrates.&#xD;
&#xD;
               4. Warfarin.&#xD;
&#xD;
               5. Sulphasalazine or rosuvastatin.&#xD;
&#xD;
         13. Current or previous participation in any other clinical trial where the subject has&#xD;
             received a dose of IMP within 1 month or 5 half-lives of the investigational medicinal&#xD;
             product (IMP), whichever is longest, prior to screening&#xD;
&#xD;
         14. Positive pregnancy test&#xD;
&#xD;
         15. Abnormal laboratory value at screening indicating a potential risk for the subject if&#xD;
             enrolled in the trial as evaluated by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Katrine Cohrt, M.Sc.</last_name>
    <phone>+46 (0) 317880560</phone>
    <email>info@vicorepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rohit Batta, M.D.</last_name>
    <phone>+46(0)317880560</phone>
    <email>info@vicorepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkview Physicians Group - Infectious Diseases</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen Horton, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Health</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - 17th Street</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lowcountry Infectious Diseases</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Río Cuarto</name>
      <address>
        <city>Río Cuarto</city>
        <state>Córdoba</state>
        <zip>X5800</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano Rosario - Centro</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2001</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuevo Hospital San Roque</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Brasília</name>
      <address>
        <city>Brasília</city>
        <zip>71681-603</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundação Universidade de Caxias do Sul</name>
      <address>
        <city>Caxias Do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas de Natal</name>
      <address>
        <city>Natal</city>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz - Paulista</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Somer</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Santa Fe de Bogotá</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice u sv. Anny v Brně</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Slaný</name>
      <address>
        <city>Slaný</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Ústí nad Labem</name>
      <address>
        <city>Ústí Nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smt. Kashibai Navale Medical College and General Hospital</name>
      <address>
        <city>Pune</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malabar Medical College Hospital and Research Centre</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elite Mission Hospital</name>
      <address>
        <city>Thrissur</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chirayu Medical College and Hospital</name>
      <address>
        <city>Bhopal</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Government Medical College and Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Noble Hospital PVT LTD</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Medical College and Chhatrapati Shivaji Maharaja Hospital</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Institute of Medical Sciences</name>
      <address>
        <city>Imphal</city>
        <state>Manipur</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Carlos Alberto Seguín Escobedo</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Arzobispo Loayza</name>
      <address>
        <city>Lima Cercado</city>
        <zip>15082</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic International - Headquarters Lima</name>
      <address>
        <city>Lima Cercado</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Philippines Medical Center</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Visayas State University Medical Center</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lung Center of the Philippines</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quirino Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Global City</name>
      <address>
        <city>Taguig</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №4&quot; of the Dnipro City Council</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №13&quot; Of Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital of Infectious Diseases</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska Kyiv City Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinnytsia City Clinical Hospital №1</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital №1 of Zhytomyr City Council</name>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>India</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

